Who
James R. Meyers
Director
Company insider
Files Form 4 as: Director, CytomX Therapeutics; Director, Vera Therapeutics; Director, Sangamo Therapeutics; Director, Arbutus Biopharma; EVP Worldwide Commercial Ops, Gilead Sciences.
In numbers
- Trades disclosed
- 99
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $14.2M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 22 Jan 2007
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,000 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,000 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,084 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,084 at $0.00 | filing |
| 25 Nov 2025filed 26 Nov 2025 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | Sangamo Therapeuticsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | Sangamo Therapeutics | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | Sangamo Therapeuticsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | Sangamo Therapeutics | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 23 May 2024filed 24 May 2024 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 1 Jun 2023filed 5 Jun 2023 | Sangamo Therapeuticsoption or derivative | SEC FORM 4 Code A | —27,750 at $0.00 | filing |
| 1 Jun 2023filed 5 Jun 2023 | Sangamo Therapeutics | SEC FORM 4 Code A | —13,900 at $0.00 | filing |
| 24 May 2023filed 26 May 2023 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 25 May 2022filed 26 May 2022 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,000 at $0.00 | filing |
| 25 Feb 2022filed 1 Mar 2022 | Sangamo Therapeuticsoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 25 Feb 2022filed 1 Mar 2022 | Sangamo Therapeutics | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
News
Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?GILD · insidermonkey.com · 22 Oct 2026Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?GILD · fool.com · 18 Oct 2026Gilead Sciences Clears Its February High at $153.54GILD · 247wallst.com · 15 Oct 2026
0 headlines in the last 90 days name James R. Meyers; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.